Update in treatment and targets in Ewing sarcoma

Gregory M Cote; Edwin Choy

doi:10.1016/j.hoc.2013.07.001

Update in treatment and targets in Ewing sarcoma

Hematol Oncol Clin North Am. 2013 Oct;27(5):1007-19. doi: 10.1016/j.hoc.2013.07.001. Epub 2013 Aug 3.

Authors

Gregory M Cote¹, Edwin Choy

Affiliation

¹ Division of Hematology Oncology, Yawkey Center for Outpatient Care, Massachusetts General Hospital, Harvard Medical School, 32 Fruit Street, Boston, MA 02114, USA.

PMID: 24093173
DOI: 10.1016/j.hoc.2013.07.001

Abstract

The improvement in outcome for patients with localized and metastatic Ewing sarcoma since the development of cytotoxic chemotherapy remains one of the most profound advances in oncology and one of the proudest achievements of sarcoma researchers. Identification of molecular targets for new treatments has become an intense area within Ewing sarcoma research. The development of improved preclinical Ewing sarcoma models and advanced molecular techniques will build on knowledge of EWS/FLI1 function, EWS/FLI1 transcription targets, and the other critical driver events in these tumors.

Keywords: Chemotherapy; Ewing sarcoma; Oncology; Treatment; Tumor.

Publication types

Review

MeSH terms

Bone Neoplasms / diagnosis
Bone Neoplasms / drug therapy*
Bone Neoplasms / etiology
Humans
Sarcoma, Ewing / diagnosis
Sarcoma, Ewing / drug therapy*
Sarcoma, Ewing / etiology